Rep. Thomas H. Kean Jr. (R-NJ) Sells BDX Stock
Thomas H. Kean Jr., a Republican Congressman from New Jersey, reported selling shares of Becton, Dickinson valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Thomas H. Kean Jr. (R-NJ) sold between $1,001 and $15,000 of Becton, Dickinson and Company ($BDX) stock on May 21, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 18, 2026.
Since the trade, $BDX is up 1.5% after 1 week, down 3.1% after 1 month and up 32.8% to date (from the $144.37 close on May 21, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Thomas H. Kean Jr. (R)
- Status:
- Member — House
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 18, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Becton, Dickinson and Company ($BDX) | Sell | May 21, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BDX
Becton, Dickinson and Company
Key Points
- On May 21, 2026, Thomas H. Kean Jr. sold shares of Becton, Dickinson valued between $1,001 and $15,000.
- Becton, Dickinson's stock closed at $180.94 the day before the reported sale, with a market capitalization of approximately $49.2 billion.
- Analysts have a consensus buy rating for Becton, Dickinson, with a mean price target of $195.67.
Get $BDX trade alerts by text
We text you when insiders, Congress or big funds trade $BDX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Becton, Dickinson and Company alert may contain errors. Disclosures
Lawmaker's Recent Trade
On May 21, 2026, Thomas H. Kean Jr., a Republican Congressman from New Jersey's 7th district, sold shares of Becton, Dickinson and Company (NYSE: BDX) valued between $1,001 and $15,000. This trade was disclosed on June 18, 2026, as part of the periodic transaction reports required under the STOCK Act.
Thomas H. Kean Jr. vs. the S&P 500
Hypothetical returns from Thomas H. Kean Jr.'s disclosed trades, not real profit or advice. How we model this.
Previous Trading Activity
This sale follows Kean's previous trade on May 14, 2026, when he bought shares of Amcor valued up to $15,000. His recent activities in the stock market reflect his ongoing engagement with investments, although this particular sale may raise questions about his current views on Becton, Dickinson.
Institutional Interest
While no peer funds reported changes in their positions in Becton, Dickinson in the latest filings, the company has seen varied institutional interest recently. For instance, Commonwealth Equity Services reduced its stake in Becton, Dickinson by 32.5% in its last 13F filing. This shift suggests a mixed sentiment among institutional investors regarding the company's stock performance.
How Becton, Dickinson and Company Stock Has Traded
Becton, Dickinson shares closed at $180.94 the day before Kean's sale, which is significantly higher than its 52-week low of about $127.59. The stock has fluctuated between $127.59 and $193.07 over the past year, indicating volatility in its trading pattern. Investors will be watching how the stock performs in the coming months, especially with the next earnings report scheduled for November 5, 2026.
Recent Earnings
In its latest earnings report, Becton, Dickinson reported revenues of approximately $22.48 billion, reflecting a revenue growth of 5.4%. The company had an earnings per share (EPS) of $5.77 and a net margin of 4.19%. These figures highlight the company's solid performance in a competitive healthcare market.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Insider Buying and Selling at Becton, Dickinson and Company
Recent insider activity at Becton, Dickinson includes sales by key executives. On June 26, 2026, Michael Feld, the Executive Vice President and Chief Revenue Officer, sold 75 shares at an average price of $152.80, totaling about $11,460. Additionally, on June 24, 2026, Garrison Michael David, the Executive Vice President and President of Medical Essentials and BioPharma, sold 1,100 shares at an average price of $145.66, valued at approximately $160,226. These transactions indicate ongoing adjustments by insiders in response to market conditions.
Analysts Set New Price Targets
Analysts have varied opinions on Becton, Dickinson. On October 7, 2026, Barclays initiated coverage with an Underweight rating and a price target of $165. Meanwhile, Citigroup maintained a Buy rating with a target of $204 on August 7, 2026. The consensus among 12 analysts currently stands at a Buy rating with a mean price target of $195.67, reflecting optimism about the company's future performance.
What Becton, Dickinson and Company Does
Becton, Dickinson and Company develops and sells a wide range of medical supplies and devices. With a strong presence in the healthcare sector, it serves various markets, including hospitals and laboratories. The company's recent trading activity and insider sales could reflect broader market trends that investors should consider.
What's Ahead for Becton, Dickinson and Company
Investors will be monitoring Becton, Dickinson closely as it approaches its next earnings date on November 5, 2026. The recent disclosures from lawmakers and insiders may provide additional context for the company's stock performance. As always, it's important to remember that the 13F filings reflect holdings as of the reporting period and may not represent current positions.
Related Filing Alerts
Source: Thomas H. Kean Jr.'s STOCK Act disclosure on $BDX (May 21, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts